Selective delivery of 10B to soft tissue sarcoma using 10B-L-borophenylalanine for boron neutron capture therapy.
Boron neutron capture therapy (BNCT) may improve the locoregional control of radio/chemoresistant tumours like soft tissues sarcomas (STS). This technique uses the 10B(n,alpha)7Li nuclear reaction to destroy tumour cells, provided that a sufficient amount of 10B may be carried selectively into them. In order to evaluate the targeting potential of 10B-L-borophenylalanine (BPA) a 10B biodistribution study was carried out in 24 Wistar rats bearing Yoshida sarcoma. Six animals received increasing intraperitoneal doses of BPA (300, 600 and 1200 mg kg-1), while the remainder received a BPA dose of 600 mg kg-1 but with a sacrifice at six different time points: 1, 2, 4, 6, 9 and 12 h. The 10B concentrations in the tumours, normal tissues and blood were analysed with neutron capture radiography (NCR). The analysis shows that 36 micrograms g-1 (+/- 4 SD) of 10B may be incorporated into the tumour, with a ratio of 13 (+/- 4 SD) versus the muscle and a ratio of 15 (+/- 3 SD) versus the blood, 6 h after an intraperitoneal injection of 600 mg kg-1 of BPA. The BPA appears to be abundantly incorporated in the tumour, and the kidney proximal tubule area. These data suggest that BNCT using BPA may provide an improved therapeutic ratio for the treatment of STS.
Pignol
J P
JP
Service de Radiothérapie, Hôpital du Hasenrain, Mulhouse, France.
Oudart
H
H
Chauvel
P
P
Sauerwein
W
W
Gabel
D
D
Prevot
G
G
D000818:Animals; D001896:Boron Compounds / Q000032:analysis* / Q000493:pharmacokinetics*; D016754:Boron Neutron Capture Therapy; D009368:Neoplasm Transplantation; D051381:Rats; D017208:Rats, Wistar; D012517:Sarcoma, Yoshida / Q000378:metabolism* / Q000532:radiotherapy
D001896:Boron Compounds